Neurocrine Promotes Samir Siddhanti to Chief Business Officer
Event summary
- Samir Siddhanti, previously VP of Business Development at Neurocrine Biosciences, has been promoted to Chief Business Officer effective July 21, 2026.
- Siddhanti led the $2.9 billion acquisition of Soleno Therapeutics and serves as Program Team Leader for direclidine, a treatment in development for schizophrenia and bipolar disorder.
- He will oversee enterprise growth strategy, business development, corporate strategy, alliance management, and program management.
The big picture
Neurocrine's promotion of Samir Siddhanti to Chief Business Officer underscores its focus on scaling its pipeline and commercial portfolio. The move comes amid a wave of consolidation in the biopharmaceutical sector, where companies are increasingly turning to strategic acquisitions and partnerships to drive growth. With a $2.9 billion acquisition under his belt and deep experience in business development, Siddhanti is well-positioned to navigate Neurocrine through its next phase of expansion.
What we're watching
- Pipeline Integration
- How Siddhanti will leverage his experience to maximize the value of Neurocrine's expanding pipeline, particularly following the Soleno Therapeutics acquisition.
- Strategic Alliances
- Whether Neurocrine can sustain its growth trajectory through continued strategic partnerships and business development initiatives under Siddhanti's leadership.
- Therapeutic Focus
- The pace at which direclidine and other muscarinic portfolio treatments advance through clinical development under Siddhanti's strategic oversight.